In summary, rHGFK1, especially when used in combination with CDDP, can inhibit the spheroid formation ability of CD90+ CSC cells, and may promote their differentiation in the presence of other chemotherapeutic agents and enhance the sensitivity of HCC cells to chemotherapeutic agents. Here, THY1 is linked to hepatocellular carcinoma.